Teresa Rossi

Dr. Teresa Rossi


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in BioFactors
Verified
Journal Article
Closed access
PDF file
MPMarta Piroddi
Marta Piroddi
Adriana AlbiniAdriana Albini
Adriana Albini
Roberto FabianiRoberto Fabiani
Roberto Fabiani
LGLisa Giovannelli
Lisa Giovannelli
Cristina LuceriCristina Luceri
Cristina Luceri
FGFrancesco Galli
Francesco Galli

7 September 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
VSValentina Sancisi
Valentina Sancisi
GMGloria Manzotti
Gloria Manzotti
MGMila Gugnoni
Mila Gugnoni
TRTeresa Rossi
Teresa Rossi
GGGreta Gandolfi
Greta Gandolfi
ACAlessia Ciarrocchi
Alessia Ciarrocchi
Aberrant reactivation of embryonic pathways is a common feature of cancer. RUNX2 is a transcription factor crucial during embryogenesis that is aberrantly reactivated in many tumors, including thyroid and breast cancer, where it promotes aggressiveness and metastatic spreading. Currently, the mechanisms driving RUNX2 expression in cancer are still largely unknown. Here we showed that RUNX2 transcription in thyroid and breast cancer requires the cooperation of three distantly located enhancers (ENHs) brought together by chromatin three-dimensional looping. We showed that BRD4 controls RUNX2 by binding to the newly identified ENHs and we demonstrated that the anti-proliferative effects of bromodomain inhibitors (BETi) is associated with RUNX2 transcriptional repression. We demonstrated that each RUNX2 ENH is potentially controlled by a distinct set of TFs and we identified c-JUN as the principal pivot of this regulatory platform. We also observed that accumulation of genetic mutations within these elements correlates with metastatic behavior in human thyroid tumors. Finally, we identified RAINs, a novel family of ENH-associated long non-coding RNAs, transcribed from the identified RUNX2 regulatory unit. Our data provide a new model to explain how RUNX2 expression is reactivated in thyroid and breast cancer and how cancer-driving signaling pathways converge on the regulation of this gene.

5 January 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GTGiovanna Talarico
Giovanna Talarico
SOstefania orecchioni
stefania orecchioni
KDKatiuscia Dallaglio
Katiuscia Dallaglio
FRFRANCESCA REGGIANI
FRANCESCA REGGIANI
PMPatrizia Mancuso
Patrizia Mancuso
Francesco BertoliniFrancesco Bertolini
Francesco Bertolini
Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models. Since Metformin is frequently used along with Aspirin or beta-blockers, we investigated the effect of Metformin, Aspirin and the beta-blocker Atenolol in several BC models. In vitro, Aspirin synergized with Metformin in inducing apoptosis of triple negative and endocrine-sensitive BC cells and in activating AMPK in BC and in white adipose tissue (WAT) progenitors known to cooperate to BC progression. Both Aspirin and Atenolol added to the inhibitory effect of Metformin against complex I of the respiratory chain. In both immune-deficient and immune-competent preclinical models, Atenolol increased Metformin activity against angiogenesis, local and metastatic growth of HER2+ and triple negative BC. Aspirin increased the activity of Metformin only in immune-competent HER2+ BC models. Both Aspirin and Atenolol, when added to Metformin, significantly reduced the endothelial cell component of tumor vessels, whereas pericytes were reduced by the addition of Atenolol but not by the addition of Aspirin. Our data indicate that the addition of Aspirin or of Atenolol to Metformin might be beneficial for BC control and that this activity is likely due to effects on both BC and microenvironment cells.

1 December 2016 in Journal of Functional Foods
Verified
Journal Article
Closed access
BBBarbara Bassani
Barbara Bassani
TRTeresa Rossi
Teresa Rossi
DSDaniela De Stefano
Daniela De Stefano
DPDaniele Pizzichini
Daniele Pizzichini
PCPaola Corradino
Paola Corradino
ABAntonino Bruno
Antonino Bruno

6 December 2014 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
TRTeresa Rossi
Teresa Rossi
CGCristina Gallo
Cristina Gallo
BBBarbara Bassani
Barbara Bassani
SCSara Canali
Sara Canali
Adriana AlbiniAdriana Albini
Adriana Albini
ABAntonino Bruno
Antonino Bruno
Specific alimentary habits, including oriental and Mediterranean diets characterized by high consumption of vegetables, fruits, cereals and, for the Mediterranean diet, olive oil, are associated with a reduction of risk of cardiovascular diseases, type 2 diabetes, neurodegenerative diseases, and some cancers. Numerous beverages contain diverse natural compounds, termed phytochemicals, that have been reported to exert antitumor, antiangiogenic, and antioxidant properties. Here we review the chemopreventive and angiopreventive properties of selected phytochemicals found in common beverages: epigallocatechin(green tea), triterpenoids (citrus juices), resveratrol (red wine), xanthohumol (beer), procyanidin (chocolate), and caffeine (coffee), focusing on their molecular mechanisms, providing "ready to drink" prevention approaches.

1 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CGCristina Gallo
Cristina Gallo
KDKatiuscia Dallaglio
Katiuscia Dallaglio
BBBarbara Bassani
Barbara Bassani
TRTeresa Rossi
Teresa Rossi
ARArmando Rossello
Armando Rossello
Adriana AlbiniAdriana Albini
Adriana Albini
Hop derived flavonoid Xanthohumol inhibits endothelial cell functions via AMPK activation